Back to results
US 2018/0002333 A1Published application
Ethynyl derivatives
AssigneeHoffmann-La Roche Inc.
InventorsBarbara BIEMANS, Wolfgang Guba, Georg Jaeschke, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira, Fionn O'Hara
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
Claims12
A compound of formula I
- wherein
- Y is C—R1′;
- R1′ is hydrogen, F or Cl;
- R1 is F or Cl;
- R2 is hydrogen or lower alkyl;
- R3 is phenyl, pyridinyl or isothiazolyl, wherein the N atom in the pyridinyl group may be in different positions, optionally substituted by one or two halogen atoms;
- R4 is hydrogen or lower alkyl;
- Het is a 5-membered heteroaryl group, containing two or three heteroatoms, selected from N,O or S, optionally substituted by lower alkyl, cycloalkyl, lower alkoxyalkyl, heterocycloalkyl, wherein the hetero-atom is O, or lower alkyl substituted by hydroxy, or is a bicyclic heteroaromatic ring, containing two or three N-heteroatoms selected from the groups
- or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
6 more elements
Dependencies are inferred from the claim text.